Slovakia
In Slovakia, diagnosis often begins with a family doctor, but long waits for specialists in cities like Bratislava or Košice delay confirmation through cognitive tests and imaging, while rural families face even fewer resources and lingering stigma. Although drugs such as donepezil and memantine are fully reimbursed, the main challenges fall on family carers, usually women, who receive limited state support and brief respite in subsidized day‑care centers. The Slovak Alzheimer Society provides vital lifelines through its cafés, helpline, and training programs, while universities and non-governmental organisations (NGOs) work through European Union (EU)‑funded projects to improve early diagnosis, develop affordable biomarker tools, and build a more inclusive future for people living with dementia.
AD Rating
Diagnostic Pathway
Specialized Care
Caregiver Support
National Policies
Access to ATT-s
Highlights
Population
Median age
Health expenditure (% of GDP)
Diagnosis
Diagnosis
Show moreThe diagnostic pathway begins with a family doctor, who initiates sequential assessments leading to specialist reviews. Standard cognitive screening tools include Slovak versions of the MMSE, MoCA, and ADAS-Cog. Structural neuroimaging via CT is widely available, while detailed MRI scans are concentrated in major university centres. Public insurance funds genetic testing for rare familial variants when ordered by certified clinical geneticists. Although evaluations are nominally free under public health insurance, high out-of-pocket costs and long specialist waits create prominent diagnostic barriers.
Diagnosis pathway
The diagnostic journey in Slovakia typically initiates in primary care with a family doctor. It follows sequential assessment steps progressing through neurological, psychiatric, and neuroimaging evaluations. Post-diagnostic support is subsequently overseen by specialist services and Alzheimer associations. Despite the presence of universal healthcare coverage across the country, access to a timely and comprehensive diagnosis remains historically uneven. This diagnostic pathway is significantly hindered by prominent training gaps, critical specialist shortages, and severe regional disparities.
The path to diagnosis involves sequential assessment steps beginning in primary care and progressing through neurological, psychiatric, and neuroimaging evaluations, with post-diagnostic support managed through specialist services and Alzheimer associations. Despite universal healthcare coverage, access to timely and comprehensive diagnosis has been uneven in the past, limited by training gaps, specialist shortages, and regional disparities.
Wait times
Slovakia does not collect or publish official data regarding dementia diagnostic waiting times. However, published surveys from Alzheimer Europe and the Organisation for Economic Co-operation and Development State of Health in the European Union 2023 report indicate that specialist waiting times in Slovakia consistently exceed European Union averages. This matches the country’s broader systemic challenge of maintaining long waiting lists for outpatient specialist care. These extensive delays mean families in cities like Bratislava or Kosice encounter significant waiting periods for specialist confirmation.
There is no official data on the waiting times in Slovakia.
Diagnosis cost
Alzheimer’s disease diagnosis is generally free for patients in Slovakia, as mandatory public health insurance covers primary care and specialist evaluations. The state does not publish an official state-level tariff or line-item cost for this process. However, data reveal that Slovakia faces high out-of-pocket payments, comprising around 20 percent of total health spending. Families frequently encounter extra private fees for specialist and diagnostic services compared to the European Union average, and resource constraints create additional diagnostic barriers.
The diagnosis of Alzheimer’s disease is generally free in Slovakia, as the country’s public health insurance (which is mandatory) covers primary care and specialist evaluations.
Currently, Slovakia does not publish an official state‑level tariff or line‑item cost specifically for Alzheimer’s disease diagnosis, but several EU and OECD data sources document major cost drivers and resource patterns: the OECD–European Commission reports that Slovakia faces high out‑of‑pocket payments (around 20% of total health spending) and frequent extra private payments for specialist and diagnostic services compared to the EU average. Additionally, MOPEAD Project (H2020) delineates barriers to early diagnosis due to “limited resources and costs” in Slovakia.
Cognitive tests
In Slovakia, most commonly used tests are:
Mini-Mental State Examination (MMSE) – Slovak version
Montreal Cognitive Assessment (MoCA) – Slovak translation
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS‑Cog)
Imaging tests
Computed tomography (CT) is widely available across Slovak regional hospitals and is commonly used as an initial structural imaging modality in the assessment of cognitive impairment and dementia. Magnetic resonance imaging (MRI), particularly in major university and tertiary centers such as Bratislava, Košice, and Martin, provides more detailed evaluation of neurodegenerative and vascular brain changes, including medial temporal (hippocampal) atrophy, white matter abnormalities, and cerebrovascular lesions. Fluorodeoxyglucose Positron Emission Tomography (FDG‑PET) is offered only in a few tertiary clinical centers such as Comenius University Hospital, Bratislava and Louis Pasteur University Hospital, Košice and it is used mostly for research or unclear clinical cases.
Genetic tests
Amyloid Precursor Protein (APP), PSEN1, and PSEN2 are routinely analysed in Slovakia for suspected familial or early‑onset Alzheimer’s disease (especially before age 65). Tests are financed under public insurance when ordered by a certified clinical geneticist.
Biomarker tests
No publicly accessible Slovakia-specific evidence was identified confirming nationwide implementation of the A/T/N biomarker framework, routine clinical use of CSF Alzheimer’s disease biomarkers, availability of amyloid or FDG-PET for confirmatory diagnosis, or concentration of biomarker testing capacity in Bratislava and Košice.
Cognitive Tests
Cognitive Tests
In Slovakia, most commonly used tests are:
Mini-Mental State Examination (MMSE) – Slovak version
Montreal Cognitive Assessment (MoCA) – Slovak translation
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS‑Cog)
Imaging Tests
Imaging Tests
Computed tomography (CT) is widely available across Slovak regional hospitals and is commonly used as an initial structural imaging modality in the assessment of cognitive impairment and dementia. Magnetic resonance imaging (MRI), particularly in major university and tertiary centers such as Bratislava, Košice, and Martin, provides more detailed evaluation of neurodegenerative and vascular brain changes, including medial temporal (hippocampal) atrophy, white matter abnormalities, and cerebrovascular lesions. Fluorodeoxyglucose Positron Emission Tomography (FDG‑PET) is offered only in a few tertiary clinical centers such as Comenius University Hospital, Bratislava and Louis Pasteur University Hospital, Košice and it is used mostly for research or unclear clinical cases.
Genetic Tests
Genetic Tests
Amyloid Precursor Protein (APP), PSEN1, and PSEN2 are routinely analysed in Slovakia for suspected familial or early‑onset Alzheimer’s disease (especially before age 65). Tests are financed under public insurance when ordered by a certified clinical geneticist.
Biomarker Tests
Biomarker Tests
No publicly accessible Slovakia-specific evidence was identified confirming nationwide implementation of the A/T/N biomarker framework, routine clinical use of CSF Alzheimer’s disease biomarkers, availability of amyloid or FDG-PET for confirmatory diagnosis, or concentration of biomarker testing capacity in Bratislava and Košice.
Treatment & Care
Treatment & care
Show moreStandard anti-dementia medications – donepezil, rivastigmine, galantamine, and memantine – are fully reimbursed by public health insurance. Specialised medical facilities like the Centrum MEMORY are rare and clustered in urban hubs, leaving rural areas dependent on generic clinics. Day-care programs and home personal assistance involve fixed patient co-payments alongside public subsidies. Residential care is provided across public and expensive private facilities, with costs shared between regional authorities, pensions, and family contributions. Palliative care is delivered nationwide through regional hospital units and hospices.
Specialized facilities and services
Specialised medical facilities, including memory clinics and dedicated diagnostic centres, are highly limited and heavily concentrated in urban hubs like Bratislava. The private non-profit hybrid Centrum MEMORY in Bratislava is the most prominent institution providing early diagnostics, outpatient care, and specialised training. Specialised memory clinics are completely absent in rural and smaller regional areas. Day and community-based services are less developed than institutional care, though regional governments support some cognitive rehabilitation and community social service centres.
Specialised medical facilities, such as memory clinics and dedicated Alzheimer’s disease diagnostic centres, are highly limited in Slovakia and primarily concentrated in major urban hubs. The most prominent institution is the MEMORY Centre (Centrum MEMORY) in the capital city, Bratislava, which has historically stood as a unique, specialised establishment providing early diagnostics, outpatient clinical care, and specialised training., While standard neurological and psychiatric outpatient clinics across the country handle general dementia care and prescriptions, specialised memory clinics are mostly absent from rural and smaller regional areas, creating a significant urban-rural gradient in diagnostic accessibility.
Day and community-based dementia services exist but are less developed than institutional care. Specialised day-care programmes and activation services for people with dementia are offered by facilities such as Centrum MEMORY, while municipalities, regions, and private providers operate day centres, home-care services, and community support programmes for older adults. Recent policy initiatives have promoted community-based social service centres in regions such as Banská Bystrica, but availability varies considerably between regions and rural areas often have fewer options.
Palliative and end-of-life care for people with advanced Alzheimer’s disease is provided through a combination of hospital palliative-care units, hospice facilities, community nursing services, and home-based care., These services are available across Slovakia rather than being confined to Bratislava, although capacity and specialist expertise vary by region. National reforms and long-term care strategies have emphasised expanding access to long-term and palliative care in response to population ageing, but challenges remain in integrating health and social care services and ensuring consistent availability throughout the country.
Regional governments (Trnava, Banská Bystrica, Žilina) also support community‑based cognitive rehabilitation services, often co‑funded by EU projects such as the European Social Fund Plus “Quality Care for Older People in Slovakia” project.
Approved medication
| Generic Name | Trade Name | Used for |
|---|---|---|
| Donepezil | Aricept, Aricept ODT, Adlarity, Eranz, Memac, Alzepil, Davia, Donecept, Donep, Donepex, Donesyn, Dopezil, Yasnal, Memorit, Pezale, Redumas, Zolpezil, Namzaric* | Donepezil is indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia. |
| Rivastigmine | Exelon, Exelon Patch, Prometax, Rivastach, Nimvastid | Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease. |
| Galantamine | Razadyne, Razadyne ER, Reminyl, Reminyl XL, Nivalin, Lycoremine, Galsya | Galantamine is indicated for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type. |
| Memantine | Namenda, Namenda XR, Ebixa, Memary, Axura, Akatinol, Maruxa, Nemdatine, Namzaric* | Treatment of adult patients with moderate to severe Alzheimer’s disease. |
*Namzaric = combination of Donepezil and Memantine
Treatment cost
Dementia medications and medical care are almost entirely covered by mandatory public health insurance, except from ATTs. However, municipal day-care centres require a user fee of five to fifteen euros per day, which is subsidised at a 60 percent rate. Home nursing and personal assistance involve a patient co-payment of five to eight euros per hour, with insurance covering roughly 70 percent. Publicly subsidised long-term residential facilities cost residents several hundred euros monthly, whereas private, specialised dementia options are substantially more expensive.
Treatment costs including medications and medical care are nearly entirely covered by the public health insurance, except from ATTs.
Municipal dementia day‑care centres (8 h/day) are €5–15 in user fee per day and are subsidised at a 60 % rate. Home nursing and personal‑assistance visits include a €5–8/hour patient co‑pay and the insurance covers about 70 %.
Residential long-term care for people with Alzheimer’s disease in Slovakia is provided through a mix of municipal, regional, non-profit, and private facilities. Costs vary considerably by region, provider, and level of dependency. Publicly subsidized facilities generally charge residents several hundred euros per month, while private and specialized dementia facilities can be substantially more expensive. Funding is typically shared among public authorities, the resident’s income/pension, and, where necessary, family contributions.
Caregiver support
Caregiver support blends national public services, local municipal aid, and non-governmental programmes. A cash caregiver allowance is provided to family members delivering full-time home care to relatives with chronic conditions or dementia. Municipalities also fund home-based respite programmes to grant temporary relief to family carers. Additionally, the Slovak Alzheimer Society provides vital lifelines by organising Alzheimer Cafés, specialised training programmes, helpline counselling, and direct psychological support for carers.
Carer support for Alzheimer’s disease in Slovakia combines national public services, local and municipal aid, and programs run by NGOs, most notably the Slovak Alzheimer Society (Slovenská Alzheimerova spoločnosť, SAS). Cash “caregiver allowance” (Opatrovateľský príspevok) is paid to family members providing full‑time home care to relatives living with chronic illness or dementia. Municipalities fund home‑based respite programs for family carers, allowing temporary relief from daily care duties. The Slovak Alzheimer Society organizes Alzheimer Cafés, training programs, carer psychological support, helpline & counselling and other.
Policy
Policy
Show moreSlovakia completely lacks an active national strategy, leaving dementia managed under generic health and social laws. Gaps are severe because information systems fail to track the realities of patients, and specialized units lack explicit training standards. No legal frameworks exist to link medical and social records or standardise patient consent. Culturally, strong social stigma and a general lack of medical awareness persist across the population. To resolve this, a new National Dementia Strategy is currently being developed under the European Union Horizon Europe initiative.
National dementia plan
Slovakia currently does not have a national dementia strategy or action plan.
Upcoming plans
Slovakia is currently developing its first National Dementia Strategy, supported through a major EU Horizon Europe initiative. According to the EU‑funded Alzheimer’s Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe (ADDIT‑CE) project, the results of the program will be used to develop the Slovak National Plan to Combat Dementia, among others.
Policy gaps
Legal barriers
Slovakia lacks a dedicated national dementia law, meaning the condition is governed under generic health and social statutes. National information systems fail to adequately capture the realities of people living with dementia, leading to limited data collection, uneven service provision, and low policy prioritisation. Specialised dementia units operate under basic nursing-home regulations without explicit recognition or training standards. Furthermore, there are no legal mechanisms to link medical and social records or standardise clinical consent for cognitive impairment cases.
Slovakia lacks a national dementia law or policy, meaning Alzheimer’s disease falls under general health and social statutes. In a recent statement to the World Health Organization (WHO), Slovak authorities acknowledged significant gaps in dementia information systems and support services, noting that national health and social information systems do not adequately capture the realities of people living with dementia. Limited data collection, uneven service provision, and insufficient policy prioritisation can contribute to delayed diagnoses and reduced visibility of people with dementia in public life. When support systems are fragmented or underdeveloped, individuals living with Alzheimer’s disease may become increasingly dependent on family caregivers, reinforcing stereotypes of helplessness and social burden rather than citizenship and inclusion.
Further, specialised dementia units operate under generic nursing‑home regulations without recognition or training standards.
Finally, there are no legal mechanisms that connect medical and social records or standardise consent for cognitive‑impairment cases.
Cultural barriers
Slovakia still experiences strong stigma surrounding dementia, with a large portion of the population unaware of its medical nature, mirroring attitudes across Eastern Europe. Research examining Slovak perceptions of Alzheimer’s disease found that attitudes toward people with Alzheimer’s disease were generally positive but less favourable than those observed in some other European populations, suggesting the persistence of underlying stereotypes and social distance.
Research
Research
Show moreAcademic research is anchored across institutions like Comenius University and the Slovak Academy of Sciences. Clinical trials are regulated nationally by the State Institute for Drug Control through the European Clinical Trials Information System. Notable innovative research includes the ADDIT-CE project developing a low-cost fluid biomarker pipeline for regional labs. Additionally, next-generation sequencing maps rare immune gene variants like TREM2, while the EWA-DB project uses machine-learning models to screen Slovak linguistic and acoustic speech patterns for early cognitive decline.
Selected academic institutions
Clinical trials and registries
Štátny ústav pre kontrolu liečiv (ŠÚKL) is the Slovak State Institute for Drug Control and serves as Slovakia’s national competent authority for clinical trials of medicinal products. It is responsible for the regulatory oversight, authorization, and supervision of clinical trials conducted in Slovakia, including studies in Alzheimer’s disease and other dementias. Clinical trial applications in Slovakia are reviewed through the European Clinical Trials Information System (CTIS) and overseen nationally by ŠÚKL in collaboration with ethics committees.
National Clinical Trials Registry – ŠÚKL
Selected innovative methods
The Horizon Europe ADDIT-CE project is establishing a non-invasive, low-cost Slovak biomarker pipeline for regional labs to detect pre-clinical amyloid pathology using fluid assays standardized to European Union criteria. Next-generation sequencing is being applied to map rare genetic variants like TREM2. Additionally, the machine-learning EWA-DB project analyses Slovak speech patterns to screen for early decline. Community projects utilise tablet-based memory training applications to reduce caregiver stress and monitor daily activities.
The Horizon Europe ADDIT‑CE project (led by Comenius University and the Slovak Academy of Sciences) is introducing non‑invasive and low‑cost CSF and plasma biomarker testing for Aβ42, p‑tau, and neurofilament light chain, with standardisation to EU A/T/N criteria. It develops a “Slovak biomarker pipeline” allowing regional labs to detect amyloid pathology in pre‑clinical patients without expensive PET imaging.
Researchers at Comenius University Hospital Bratislava and the Institute of Neuroimmunology (SAS) apply next‑generation sequencing and gene‑panel analysis to identify rare Alzheimer’s disease variants (APP, PSEN1/2, TREM2) in the Slovak population. The 2022 study TREM2 Coding Variants in Slovak Alzheimer’s Disease Patients was among the first Central‑European projects to map microglial immune gene mutations in sporadic Alzheimer’s disease.
The EWA‑DB project (Early Warning Alzheimer Database) developed by Pavol Jozef Šafárik University and the Technical University of Košice uses machine‑learning analysis of Slovak speech and language to identify mild cognitive impairment and early Alzheimer’s disease. It combines acoustic and linguistic markers with clinical data to train AI models for digital screening.
Community projects in Banská Bystrica and Trnava regions (testing under the ESF Plus “Quality Care for Older People in Slovakia” programme) use tablet‑based apps for memory training and remote supervision by carers. Early evaluation shows improved daily activity monitoring and reduced carer stress
Bratislava and Brno research ecosystems are jointly developing AI‑augmented screening and imaging tools for early Alzheimer’s disease through the ADDIT‑CE strategy, supported by Geneton and BioVendor (Slovak biotech companies).
Support
Support
Show moreCommunity support is driven by the Slovak Alzheimer Society, Charita Slovakia, and the Mental Health League. The Slovak Alzheimer Society provides helplines, training courses, and Alzheimer Cafés to relieve caregiver strain. Key initiatives include the EWA-DB project, which collects language recordings via a mobile app to train early-detection AI models. Concurrently, the Quality Care for Older People project funds regional social centres providing assisted home care, transport, and smart monitoring wristbands. No dedicated dementia media outlets exist.
Selected national associations, patient family associations, NGOs:
Selected initiatives
The Early Warning Alzheimer Database collaborative initiative utilizes a mobile application to record native language tasks, building a massive baseline to train machine-learning models to spot early signs of cognitive impairment. Concurrently, the Quality Care for Older People in Slovakia project expands regional long-term support. It funds community-based social service centres that integrate assisted home care, outpatient services, transport, and smart-health monitoring technologies like wristbands to ensure independent living.
The Early Warning Alzheimer Database (EWA-DB) is an innovative research and development tool aimed at detecting neurodegenerative disorders like Alzheimer’s and Parkinson’s disease through speech analysis., Developed as a collaborative effort involving the Slovak Academy of Sciences, this initiative utilizes a mobile application to record participants performing specific language tasks, such as describing images. The resulting database acts as a massive baseline to help researchers train AI models to spot the subtlest early warning signs of cognitive impairment long before clinical symptoms fully manifest.
Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /home/bcdafabe/public_html/wp-content/themes/bricks-child/functions.php on line 752
Quality Care for Older People in Slovakia is focused on modernizing and expanding long-term support for Slovakia's aging population, notably through pilots like those in the Banská Bystrica region. The project sets up community-based social service centers that bridge the gap between healthcare and social support for vulnerable older citizens. Instead of relying solely on overburdened institutional care, this program finances localized, targeted solutions—such as assisted home care, outpatient services, transport support, and even integrated smart-health technologies (like monitoring wristbands). The goal is to provide aging individuals with personalized financial, social, and medical care so they can live safely and with dignity in their own homes for as long as possible.
Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /home/bcdafabe/public_html/wp-content/themes/bricks-child/functions.php on line 752
Dedicated media outlets
There are no dedicated media outlets or channels focused exclusively on Alzheimer’s disease or other dementias. Slovak Alzheimer’s Society provides coverage through their website and social media.
